Eradication of HIV in infected patients: Some potential approaches

Medical Science Monitor

Volumn 10, Issue 7, 2004, Pages

  Yang, Quan En ^a  

^a SAIC FREDERICK INC   (United States)

Author keywords

Antiretroviral therapy; Cytotoxic chemotherapy; Eradication of HIV; Gene therapy; Human immunodeficiency virus (HIV); Immunoactivation; Persistent infection

Indexed keywords

ALKYLATING AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIMETABOLITE; ANTIRETROVIRUS AGENT; BACTERIAL TOXIN; BUSULFAN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYDROXYUREA; IMMUNOTOXIN; INTERLEUKIN 2; INTERLEUKIN 7; MERCAPTOPURINE; METHOTREXATE; MONOCLONAL ANTIBODY; NEW DRUG; OLIGONUCLEOTIDE; PEPTIDE T; PHORBOL ESTER; PLANT TOXIN; PROSTRATIN; PROTEINASE INHIBITOR; RECOMBINANT INTERLEUKIN 2; RIBONUCLEOTIDE REDUCTASE; RIBOZYME; SMALL INTERFERING RNA; TIOGUANINE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CHEMOTHERAPY; CLINICAL TRIAL; DISEASE COURSE; DRUG POTENTIATION; ERADICATION THERAPY; GENE THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSTIMULATION; IMMUNOTHERAPY; MULTIDRUG RESISTANCE; NONHUMAN; PERSISTENT INFECTION; REVIEW; SIDE EFFECT; TISSUE INJURY; UNITED STATES; VIRUS REPLICATION; VIRUS STRAIN;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BONE MARROW TRANSPLANTATION; CLINICAL TRIALS; GENE THERAPY; HIV; HIV INFECTIONS; HUMANS; IMMUNOTOXINS; RNA, SMALL INTERFERING; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION, HOMOLOGOUS; VIRUS LATENCY; VIRUS REPLICATION;

EID: 3343024503     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (177)

1. Pantaleo G, Graziosi C, Demarest JF et al: HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature, 1993; 362: 355-58
2. Perelson AS, Neumann AU, Markowitz M et al: HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science, 1996; 271: 1582-86
3. Sharkey ME, Teo I, Greenough T et al. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med, 2002; 6: 76-81
4. Patel PH, Preston BD: Marked infidelity of human immunodeficiency virus type 1 reverse transcriptase at RNA and DNA template ends. Proc Natl Acad Sci USA, 1994; 91: 549-53
5. Kavlick MF, Wyvill K, Yarchoan R, Mitsuya H: Emergence of multi-dideoxynucleoside-resistant human immunodeficiency virus type1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy. J Inf Dis, 1998; 177: 1506-13
6. Cohen OJ, Fauci AS. Transmission of drug-resistant strains of HIV-1: unfortunate, but inevitable. Lancet, 1999; 354: 697-98
7. Hecht FM, Grant RM, Petropoulos CJ et al: Brief report: sexual transmission of an HIV-1 variant resistant to multiple reverse transcriptase and protease inhibitors. N EngJ Med, 1998; 339: 307-11
8. Grant RM, Hecht FM, Warmerdam M et al: Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA, 2002; 288: 181-88
9. Rey MA, Girard PM, Harzie M et al: HIV-1 and HIV-2 double infection in French homosexual male with AIDS-related complex (Paris, 1985). Lancet, 1987; 1(8529): 388-89
10. Georgoulias V, Fountouli D, Karvela-Agelakis A et al: HIV-1 and HIV-2 double infection in Greece. Ann Intern Med, 1988; 108: 155
11. Takehisa J, Zekeng L, Ido E et al: Various types of HIV mixed infections in Cameroon. Virol, 1998; 245: 1-10
12. Koelsch KK, Smith DM, Little SJ et al: Clade B HIV-1 superinfection with wild-type virus after primary infection with drug-resistant clade B virus. AIDS, 2003; 17: F11-F16
13. + T-cell responses containing replication of the primary virus. Nature, 2002; 420: 434-39
14. Jost S, Bermard MC, Kaiser L et al: A patient with HIV-1 superinfection. N Engl J Med, 2002; 347: 731-36
15. Le Guern M, Levy JA: Human immunodeficiency virus (HIV) type 1 can superinfect cells: Psuedotype virions produced with expanded cellular host range. Proc Natl Acad Sci USA, 1992; 89: 363-67
16. Blackard JT, Cohen DE, Mayer KH: Human immunodeficiency virus superinfection and recombination: Current state of knowledge and potential clinical consequences. Clin Inf Dis, 2002; 34: 1108-14
17. McCarthy M: HIV vaccine fails in phase 3 trial. Lancet, 2003; 361: 755-56
18. Bhardwaj N, Walker BD: Immunotherapy for AIDS virus infections: cautious optimism for cell-based vaccine. Nat Med, 2003; 9: 13-14
19. Palella FJ, Delaney KM, Moorman AC et al: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Eng J Med, 1998; 338: 853-60
20. Hogg RS, Heath KV, Yip B et al: Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA, 1998; 279: 40-54
21. Lampe FC, Johnson MA, Lipman M et al: Viral breakthrough after suppression with highly active antiretroviral therapy: experience from 233 individuals with viral loads of less than 50 copies/ml followed for up to 4 years. AIDS 2003; 17: 768-70
22. Janssen RS, Onorato IM, Valdiserri RO et al: Advancing HIV prevention: New strategies for a changing epidemic - United States, 2003 MMWR, 2003; 53: 329-32
23. Blower SM, Aschenbach AN, Kahn JO: Predicting the transmission of drug-resistant HIV: comparing theory with data. Lancet Inf Dis, 2003; 3: 10-11
24. Velasco-Hernandez JX, Gershengorn HB, Blower SM: Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? Lancet Infect Dis, 2002; 8: 487-93
25. Chun TW, Davey RT Jr, Engel D et al: Re-emergence of HIV after stopping therapy. Nature, 1999; 401: 874-75
26. Hawkins DA, Asboe D, Barlow K, Evans B: Seroconversion to HIV-1 following a needlestick injury despite combination post-exposure prophylaxis. J Inf, 2001; 43: 12-18
27. Chun TW, Davey RT, Ostrowski M et al.: Relationship between pre-existing viral reservoirs and the re-emergence of plasma verimia after discontinuation of highly active anti-retroviral therapy. Nat Med, 2000; 6: 757-61
28. Chun TW, Fauci AS: Latent reservoirs of HIV: obstacles to the eradication of virus. Proc Natl Acad Sci USA, 1999; 96: 10958-61
29. Strain MC, Günthard HF, Havlir DV et al: Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence PNAS, 2003, 100: 4819-24
30. Wong JK, Hezareh M, Gunthard HF et al: Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science, 1997; 278: 1291-95
31. Saitoh A, Hsia K, Fenton T et al: Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children. J Inf Dis, 2002; 185: 409-16
32. Persaud D, Pierson T, Ruff C et al A stable reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children. J Clin Inves, 2000; 105: 995-1003
33. Chun TW, Justement S, Lempicki RA et al: Gene expression and viral production in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals. Proc Natl Acad Sci USA, 2003; 100: 1908-13
34. + T cells. Nat Med, 2003; 9: 727-28
35. Furtado MR, Callaway DS, Phair JP, et al: Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Eng J Med, 1999; 340: 1614-22
36. Schrager LK, D'Souza MP: Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA, 1998; 280: 67-71
37. Aquaro S, Caliò R, Balzarini J et al: Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir. Antivir Res, 2002; 55: 209-25
38. Takeda A, Tuazon CU, Ennis FA: Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science, 1988; 242: 580-83
39. Athanassakis I, Protopapadakis E, Vassiliadis S: Localization of pepstatin's inhibitory action during Fc-mediated antibody internalization: possible implications for antibody-mediated viral transmission. Cell Immunol, 2000; 199: 81-88
40. Sonza S, Mutimer HP, Oelrichs R et al: Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active antiretroviral therapy AIDS, 2001; 15: 17-22
41. Lambotte O, Taoufik Y, de Goer MG et al: Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy. J Acquir Immune Defic Syndr, 2000; 23: 114-19
42. Hanly A, Petito CK: HLA-DR-positive dendritic cells of the normal human choroids plexus: a potential reservoir of HIV in the central nerve system. Hum Pathol, 1998; 29: 88-93
43. Zhang H, Dornadula G, Beumont M et al: Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med, 1998; 339: 1803-9
44. Blankson JN, Persaud D, Siliciano RF: The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med, 2002; 53: 557-93
45. Bell P, Montaner LJ, Maul GG: Accumulation and intranuclear distribution of unintegrated human immunodeficiency virus type 1 DNA. J Virol, 2001; 75: 7683-91
46. Poon B, Chen ISY: Human immunodeficiency virus type 1 (HIV-1) Vpr enhances expression from unintegrated HIV-1 DNA. J Virol, 2003; 77: 3962-72
47. Sherman MP, de Noronha CM, Eckstein LA et al: Nuclear export of Vpr is required for efficient replication of human immunodeficiency virus type 1 in tissue macrophages. J Virol, 2003;77: 7582-89
48. +) T cells are infected in human immunodeficiency virus type 1-infected individuals. J Virol, 1999; 73: 6430-35
49. Albrecht MA, Wilkin TJ, Coakley EP, Hammer SM: Advances in antiretroviral therapy. Top HIV Med, 2003; 11: 97-127
50. Lori F, Malykh A, Cara A et al: Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science, 1994; 266: 801-5
51. Khanna KV, Whaley KJ, Zeitlin L et al: Vaginal transmission of cell-associated HIV-1 in the mouse is blocked by a topical, membrane-modifying agent. J Clin Invest, 2002; 109: 205-11
52. Froeyen M, Herdewijn P: RNA as a target for drug design, the example of Tat-TAR interaction Curr Top Med Chem, 2002; 2: 1123-45
53. Chao SH, Fujinaga K, Marion JE et al: Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem, 2000; 275: 28345-48
54. Wang D, De La Fuente C, Deng L et al: Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors. J Virol, 2001; 75: 7266-79
55. Pisell TL, Ho O, Lee G, Butera ST: Spectrum of cdk-9 inhibitor activity against HIV-1 replication among various models of chronic and latent infection. Antivir Chem Chemother, 2001; 12(Suppl.1): 33-41
56. Ruff MR, Melendez-Guerrero LM, Yang QE et al: Peptide T inhibits HIV-1 infection mediated by the chemokine receptor-5 (CCR5). Antiviral Res, 2001; 52: 63-75
57. Ruff MR, Polianova M, Yang QE et al: Update on D-Ala-Peptide T-Amide (DAPTA): A viral entry inhibitor that blocks CCR5 chemokine receptors. Curr HIV Res, 2003; 1: 51-67
58. Mack KD, Jin X, Yu S et al: HIV insertion within and proximal to host cell genes are a common finding in tissues containing high levels of HIV DNA and macrophage-associate p24 antigen expression. J Acquir Immune Defic Syndr, 2003; 33: 308-20
59. Schroder A et al: HIV-1 integration in the human genome favors active genes and local hotspots. Cell, 2002; 110: 521-29
60. Jordan A, Bisgrove D, Verdin E: HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. The EMBO, 2003; 22: 1868-77
61. Carteau S, Hoffmann C, Bushman F: Chromosome structure and human immunodeficiency virus type 1 cDNA integration: centromeric alphoid repeats are a disfavored target. J Virol, 1998; 72: 4005-14
62. Borvak J, Chou CS, Bell K et al: Expression of CD25 defines peripheral blood mononuclear cells with productive versus latent HIV infection. J Immunol, 1995; 155: 3196-204
63. + T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med, 1999; 5: 651-55
64. Blankson J, Siliciano RF: Interleukin 2 treatment for HIV infection. JAMA, 2000; 284: 236-68
65. Davey RT, Murphy RL, Graziano FM et al: Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy. JAMA, 2000; 284: 183-89
66. Kulkosky J, Pomerantz RJ: Approaching eradication of highly active antiretroviral therapy-persistent human immunodeficiency virus type-1 reservoirs with immune activation therapy. Clin Inf Dis, 2002; 35: 1520-26
67. Kulkosky J, Nunnari G, Otero M et al: Intensification and stimulation therapy for human immunodeficiency virus type-1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. J Inf Dis, 2002; 186: 1403-11
68. Fraser C, Ferguson NM, Ghani AC et al: Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs. AIDS, 2000; 14: 659-69
69. Pau AK, Tavel JA: Therapeutic use of interleukin-2 in HIV-infected patients. Curr Opion Pharmacol, 2002; 2: 433-39
70. Zanussi S, Bortolin MT, Tirelli U et al: Effects of 2-year antiretroviral combination therapies on HIV-1 DNA levels. J Acquir Immune Defic Syndr, 2000; 23: 439-40
71. S: CPCRA 059. J Acquir Immune Defic Syndr, 2002; 29: 221-31
72. Stellbrink HJ, van Lunzen J, Westby M et al: Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial). AIDS, 2002; 16: 1479-87
73. Lafeuillade A, Poggi C, Chadapaud S et al: Pilot study of a combination of highly active antiretroviral therapy and cytokines to induce HIV-1 remission. J Acquir Immune Defic Syndr, 2001; 26: 44-55
74. Levy Y, Durier C, Krzysiek R et al: Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial. AIDS, 2003; 17: 343-51
75. Stellbrink HJ, van Lunzen J, Westby M et al: Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial). AIDS, 2002; 16: 1479-87
76. + T cells in vivo after IL-2 treatment of patients with HIV infection. PNAS, 2002; 99: 10712-17
77. 3. Vanguard study group. J Inf Dis, 2000; 181: 1614-21
78. Katlama C, Carcelain G, Duvivier C et al: Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy: the ILSTIM study - ANRS 082. AIDS, 2002; 16: 2027-34
79. Lacabaratz-Porret C, Urrutia A, Doisne JM et al: Impact of antiretrovitral therapy and changes in virus load on human immunodeficiency virus (HIV)-specific T cell responses in primary HIV infection. J Inf Dis, 2003; 187: 748-57
80. Marchetti G, Meroni L, Varchetta S et al: Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment. J Inf Dis, 2002; 186: 606-16
81. + T cells in vivo after IL-2 treatment of patients with HIV infection. Proc Natl Acad Sci USA, 2002; 99: 10712-17
82. + patients. Biomed Pharmacother, 2000; 54: 316-20
83. Levy Y, Durier C, Krzysiek R et al: Effects of interleukin-2 therapy combined tied with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial. AIDS, 2003; 17: 343-51
84. + lymphocyte numbers but does not enhance responses to immunization: Results of A5046s. J Inf Dis, 2003; 187: 320-25
85. Pakker NG, Kroon ED, Roos MT et al: Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS study group. AIDS, 1999; 13: 203-12
86. Gea-Banadoche JC, Clifford LH: Immune reconstitution in HIV infection. AIDS, 1999; Suppl.A: S25-S38
87. Dybul M, Hidalgo B, Chun TW et al: Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection. J Inf Dis, 2002; 185: 61-68
88. Emery S, Abrams DA, Cooper DA et al: The evaluation of subcutaneous proleukin® (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. Controlled Clinical Trials, 2002; 23: 198-220
89. Brooks DG, Hamer DH, Arlen PA et al: Molecular characterization, reactivation, and depletion of latent HIV. Immunity, 2003; 19: 413-23
90. Poliano MT, Ruscetti FW, Pert CB et al: Antiviral and immunological benefits in HIV patients receiving intranasal peptide T (DAPTA). Peptides, 2003; 24: 1093-98
91. Klinman DM, Krieg A, Conover J et al: Effect of cyclophosphamide, total irradiation, and zidovudine on retrovirus proliferation and disease progression in murine AIDS. AIDS Res Hum Retroviruses, 1992; 8: 101-6
92. Count L, La Nasa G, Arras M et al: Allogeneic bone marrow transplantation combined with multiple anti-HIV-1 treatment in a case of AIDS. Bone Marrow Transplant, 1993; 12: 669-71
93. Holland HK, Saral R, Rossi JJ et al: Allogeneic bone marrow transplantation, zidovudine, and human immunodeficiency virus type-1 (HIV-1) infection. Ann Int Med, 1989; 111: 973-81
94. Lane HC, Zunich KM, Wilson W et al: Syngeneic bone marrow transplantation and adoptive transfer of peripheral blood lymphocytes combined with zidovudine in human immunodeficiency virus (HIV) infection. Ann Intern Mad, 1990; 113: 512-19
95. + peripheral blood progenitor cells transplantation in an HIV/HCV co-infected patient with acute myeloid leukemia. Exp Hematol, 2002; 30: 279-84
96. Hužička I: Could bone marrow transplantation cure AIDS?: review. Med Hypotheses, 1997; 52: 247-57
97. Hernigou P, Marce D, Julieron A et al: Bone sterilization by radiation and the HIV virus. Rev Chir Orthop Reparatrice Appar Mot, 1993; 79: 445-51
98. Little RF, Pittaluga S, Grant N et al: Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood, 2003; 101: 4653-59
99. Borvak J, Chou CS, Van Dyke G et al: The use of cyclosporine, FK506, and SDZ NIM811 to prevent CD25- quiescent peripheral blood mononuclear cells from producing human immunodeficiency virus. J Inf Dis, 1996; 174: 850-53
100. Simard C, Jolicoeur P: The effect of anti-neoplastic drugs on murine acquired immunodeficiency syndrome. Science, 1991; 251: 305-8
101. Smith C, Lilly S, Miralles GD: Treatment of with HIV infection with cytoreductive agents. AIDS Res Hum Retroviruses, 1998; 14: 1305-13
102. Yang Q, Li K, Mikovits JA: Eradication of HIV-1 infected cells by combination of antimetabolic cytotoxic chemotherapy and antiviral chemotherapy in vitro: A pilot study. J Inf Dis, 2002; 186: 706-9
103. Lori F, Malykh A, Foli A et al: Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance. AIDS Res Hum Retrovir, 1997; 13: 1403-9
104. Ravot E, Lisziewicz J, Lori F: New uses for old drugs in HIV infection: the role of hydroxyurea, cyclosporine and thalidomide. Drug, 1999; 58: 953-63
105. Lisziewicz J, Rosenberg E, Lieberman J et al: Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med, 1999; 340: 1683-84
106. Lisziewicz J, Foli A, Wainberg M, Lori F: Hydroxyurea in the treatment of HIV infection: Clinical efficacy and safety concerns. Drug Saf, 2003; 26: 605-24
107. Lafeuillade A, Hittinger G, Chadapaud S et al: The HYDILE trial: efficacy and tolerance of a quadruple combination of reverse transcriptase inhibitors versus the same regimen plus hydroxyurea of hydroxyurea and interleukin-2 in HIV-infected patients failing protease inhibitor-based combination. HIV Clin Trials, 2002; 3: 263-71
108. Bartlett JA, Miralles GD, Sevin AD et al: Addition of cyclophosphamide to antiretroviral therapy does not diminish the cellular reservoir in HIV-infected persons. AIDS Res Hum Retrovir, 2002; 18: 535-43
109. Chun TW, Carruth L, Finzi D et al: Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature, 1997; 387: 185-88
110. Zhang L, Ramramam B, Tenner-Racz K et al: Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Eng J Med, 1999; 278: 1291-95
111. Pui CH, Evans WE: Drug therapy: acute lymphoblastic leukemia. N Engl J Med, 1998; 339: 605-15
112. Elion GB: The purine path to chemotherapy. Science, 1989; 244: 41-47
113. Steinberg AD, Plotz PH, Wolff SM et al: Cytotoxic drugs in treatment of nonmalignant diseases. Ann Intern Med, 1992; 76: 619-42
114. Nilsson A, De Milito A, Engström Pär et al: Current chemotherapy protocols for childhood acute lymphoblastic leukemia induce loss of humoral immunity to viral vaccination antigens. Pediatrics, 2002; 109: e91
115. Yang Q: Human immunodeficiency virus reservoir might be actively eradicated as residual malignant cells by cytotoxic chemotherapy. Medical Hypotheses, 2004; 62: 358-63
116. Jing N, Xu X: Rational drug design of DNA oligonucleotides as HIV inhibitors. Curr Drug Targets Infect Disord, 2001; 1: 79-90
117. Agrawal S, Ikeuchi T, Sun D et al: Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodideoxynucleotides and their phosphorothioate analogues. Proc Natl Acad Sci USA, 1989; 86: 7790-94
118. Mautino M, Morgan RA: Enhanced inhibition of human immunodeficiency virus type-1 replication by novel lentiviral vectors expressing human immunodeficiency virus type 1 envelope antisense RNA. Hum Gene Ther, 2002; 13: 1027-37
119. Sei S, Yang Q, O'Neill D et al: Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain. J Virol, 2000; 74: 4621-33
120. Boado RJ, Tsukamoto H, Pardridge WM: Drug delivery of antinsense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS. J Pharm Sci, 1998; 87: 1308-15
121. Düzgünes N, Stmöes S, Konopka K et al: Delivery of novel macromolecular drugs against HIV. Expert Opin Biol Ther, 2001; 1: 949-70
122. Novina CD, Murray MF, Dykxhoorn DM et al: siRNA-directed inhibition of HIV-1 infection. Nat Med, 2002; 8: 681-86
123. Elbashir SM, Harborth J, Lendeckel W et al: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nat. 2001; 411: 494-98
124. Miyagishi M, Hayashi M, Taira K: Comparison of the suppressive effects of antisense oligonucleotides and siRNA directed against the same targets in mammalian cells. Antisense Nucleic Acid Drug Dev, 2003; 13: 1-7
125. Kitabwalla M, Ruprecht RM: RNA interference-A new weapon against HIV and Beyond. N Eng J Med, 2002; 347: 1364-67
126. Qin XF, An DS, Chen IS, Baltimore D: Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. PNAS, 2003; 100: 183-88
127. Jaque JM, Triques K, Stevenson M: Modulation of HIV-1 replication by RNA interference. Nature, 200; 418: 435-38
128. Lee NS, Dohjima T, Bauer G et al: Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol, 2002; 20: 500-5
129. Rossi JJ: The application of ribozymes to HIV infection. Curr Opin Mol Ther, 1999; 1: 316-22
130. Bai J, Bands N, Lee NS et al: RNA-based anti-HIV-1 gene therapeutic constructs in SCID-hu mouse model. Mol Ther, 2002; 6: 770-82
131. Däzgünes N, Stmöes S, Slepushkin V et al: Enhanced inhibition of HIV-1 replication in macrophages by antisense oligonucleotides, ribozymes and acyclic nucleoside phosphonate analogs delivered in pH-sensitive liposomes. Nucleosides, Nucleotides & Nucleic Acid, 2001; 20: 515-23
132. Press OW: Prospects for the management of Non-Hodgkin's lymphomas with monoclonal antibodies and immunoconjugates. Cancer J Sci Am, 1998; 4: S19-S26
133. Kaminski MS, Estes J, Zasadny KR et al: Radioimmunotherapy with iodine 1311 tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood, 2000; 96: 1259-66
134. Newton DL, Hansen HJ, Liu H et al: Specifically CD22 receptor of human B-cell lymphomas with RNA damaging agents. Oncol Hematol, 2001; 39: 79-86
135. Hursey M, Newton DL, Hansen HJ et al: Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents: A new generation of therapeutics. Leuk Lymphoma, 2002; 43: 953-59
136. Saavedra-Lozano J, McCoig C, Xu J et al: An anti-CD45RO immunotoxin kills latently infected human immunodeficiency virus (HIV) CD4 T cells in the blood of HIV-positive persons. J Inf Dis, 2002; 185: 306-14
137. McCoig C, Van Dyke G, Chou CS et al: An anti-CD45RO immunotoxin eliminates T cells latently infected with HIV-1 in vitro. Proc Natl Acad Sci USA, 1999; 96: 11482-85
138. Borvak J, Chou CS, Bell K et al: Expression of CD25 defines peripheral blood mononuclear cells with productive versus latent HIV infection. J Immunol, 1995; 155: 3196-204
139. Bell KD, Ramilo O, Vitetta ES: Combined use of an immunotoxin and cyclosporine to prevent both activated and quiescent peripheral blood T cells from producing type 1 human immunodeficiency virus. Proc Natl Acad Sci USA, 1993; 90: 1411-15
140. st international workshop on HIV persistence during therapy; 2003 December 10-12; French West Indies
141. Dillman RO: Monoclonal antibody therapy for lymphoma: an update. Cancer Pract, 2001; 9: 71-80
142. Schnell R, Borcchmann P, Schulz H, Engert A: Current strategies of andbody-based treatment in Hodgkin's disease. Ann Oncol, 2002; 13(Suppl.): 57-66
143. McCune SL, Gockerman JP, Rizzieri DA: Monoclonal antibody therapy in the treatment of non-Hodgkin lymphoma. JAMA, 2001; 286: 1149-52
144. Pinter C, Beltrami S, Stoiber H et al: Interference with complement regulatory molecules as a possible therapeutic strategy in HIV infection. Exp Opin Invest Drugs, 2000; 2: 199-205
145. Pinter C, Siccardi AG, Longhi R, Clicio A: Direct interaction of complement factor H with the C1 domain of HIV type 1 glycoprotein 120. AIDS Res Hum Retroviruses, 1995; 11: 577-88
146. Pinter C, Siccardi AG, Lopalco L et al: HIV glycoprotein 41 complement factor H interact with each other share functional as well as antigenic homology. AIDS Res Hum Retroviruses, 1995; 11: 971-80
147. Stoiber H, Ebenbichler C, Schneider R et al: Interaction of several complement proteins with gp120 gp41, the two envolope glycoproteins of HIV-1. AIDS, 1995; 9: 19-26
148. Shedlock DJ, Shen H: Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science, 2003; 300: 337-39
149. Sun JC, Bevan MJ: Defective CD8 T cell memory following acute infection without CD4 T cell help. Science, 2003; 300: 339-42
150. Zajac AJ, Blattman JN, Murali-Krishna K et al: Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med, 1998; 188: 2205-13
151. + T cells but confers minimal survival advantage on CD4-deficient mice. Proc Natl Acad Sci USA, 2000; 97: 2725-30
152. + T cells expanded by post-exposure vaccination of γ-herpesvirus-infected CD4-deficient mice. J Immunol, 2002; 168: 3477-83
153. + cytotoxic T-cell responses during chronic viral infection. J Virol, 1994; 68: 8056-63
154. + cell anti-HIV factor in CD8+ cell granules. Blood, 2003; 102: 180-83
155. Rosenberg ES, Altfeld M, Poon SH et al: Immune control of HIV-1 after early treatment of acute infection. Nature, 2000; 407: 523-26
156. + T lymphocytes. Proc Natl Acad Sci USA, 2000; 97: 3382-87
157. ++ T cell responses associated with control of viremia. Science, 1997; 278: 1447-50
158. Liszieivicz J, Rosenberg E, Lieberman J et al: Control of HIV despite the discontinuation of antiretroviral therapy. N Eng J Med, 1999; 340: 1683-84
159. ++ T cell responses. J Clin Invest, 2003; 111: 1673-81
160. Lisziewicz J, Gabrilovich DI, Varga G et al: Induction of potent human immunodeficiency virus type 1-specific T-cell-restricted immunity by genetically modified dendritic cells. J Virol, 2001; 75: 7621-28
161. + T cell responses by dendritic cells loaded with HIV-1 proteins. J Inf Dis, 2003; 187: 315-19
162. Robbins GK, Addo MM, Troung H et al: Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization. AIDS, 2003; 17: 1121-26
163. Severino ME, Sarkis PTN, Walker BD, Yang OO: Chimeric immune receptor T cells bypass class 1 requirements and recognize multiple cell types relevant in HIV-1 infection. Virol, 2003; 306: 371-75
164. Gilliet M, Kleinhans M, Lantelme E et al: Internodal injection of semimature monocyte-derived dendritic cells induces T helper type 1 responses to protein neoantigen. Blood, 2003; 102: 36-42.
165. + T cells and monocytes elicited by immunization of rhesus monkeys with antigen-pulsed dendritic cells control SIV replication. AIDS Res Hum Retroviruses, 2002; 18: 143-48
166. Lu W, Wu X, Lu Y et al: Therapeutic dendritic-cell vaccine for simian AIDS. Nat Med, 2003; 9: 27-32
167. Lori F, Guallini P, Galluzzi L, Lisziewicz J: Gene therapy approaches to HIV infection. Am J Pharmacogenomics, 2002; 2: 245-52
168. Mautino MR: Lentiviral vectors for gene therapy of HIV-1 infection. Curr Gene Ther, 2002; 2: 23-43
169. Mautino MR, Morgan RA: Gene therapy of HIV-1 infection using lentiviral vectors expressing anti-HIV-1 genes. AIDS Patient Care STDS, 2002; 16: 11-26
170. Vocero-Akbani AM, Heyden NV, Lissy NA et al: Killing HIV-1 infected cells by transduction with an HIV protease-activated caspase-3 protein. Nat Med, 1999; 5: 29-33
171. Mautino MR, Morgan RA: Enhanced inhibition of human immunodeficiency virus type 1 replication by novel lentiviral vectors expressing human immunodeficiency virus type 1 envelope antisense RNA. Hum Gene Ther, 2002; 13: 1027-37
172. Zhang L, Yu W, He T et al: Contribution of human -defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor. Science, 2002; 298: 995-1000
173. Lin S-L, Ying S-Y: D-RNAi (Messenger RNA-antisense DNA Interference) as a novel defense system against cancer and vital infections. Curr Cancer Drug Targets, 2001; 1: 241-47
174. Lin S-L, Chuong C-M, Ying S-Y: A novel mRNA-cDNA interference phenomenon for silencing bcl-2 expression in human LNCaP cells. BBRC, 2001; 281: 639-44
175. Seidman MM, Glazer PM: The potential for gene repair via triple helix formation. J Clin Invest, 2003; 112: 487-94
176. Yao MC, Fuller P, Xi X: Programmed DNA deletion as an RNA-guided system of genome defense. Science, 2003; 300: 1581-84
177. Severino ME, Sarkis PTN, Walker BD, Yang OO: Chimeric immune receptor T cells bypass class I requirements and recognize multiple cell types relevant in HIV-1 infection. Virology, 2003; 306: 371-75